Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer

Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective

WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours

Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers

Circulating tumour DNA can guide adjuvant immunotherapy for mismatch repair-deficient tumours

Penpulimab in combination with chemotherapy for metastatic nasopharyngeal cancer shows positive results

Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer

EGFR shows to be a promising therapeutic target in NF1 mutant melanoma

Intraoperative radiotherapy: The Medical City experience

ELCC 2025: Latest in EGFR positive NSCLC